| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CPA inhibitor (N-acyl-N-hydroxy-β-phenylalanines) targets carboxypeptidase A (CPA) with varying Ki values: compound 3a (Ki = 0.35 μM), compound 3b (Ki = 0.42 μM), compound 3c (Ki = 0.58 μM), compound 3d (Ki = 0.71 μM), compound 3e (Ki = 0.95 μM) [1]
|
|---|---|
| ln Vitro |
CPA inhibitor (N-acyl-N-hydroxy-β-phenylalanines) exhibited potent in vitro inhibitory activity against carboxypeptidase A (CPA). All tested analogs showed dose-dependent inhibition of CPA, with compound 3a being the most active (Ki = 0.35 μM) and compound 3e the least active (Ki = 0.95 μM) among the series. The inhibition was determined to be competitive, as indicated by Lineweaver-Burk plots showing increased Km values without changes in Vmax, suggesting binding of the inhibitors to the active site of CPA [1]
|
| Enzyme Assay |
The enzyme activity assay for CPA inhibition was performed using Hippuryl-L-phenylalanine as the substrate. The reaction mixture contained a suitable buffer, CPA enzyme, different concentrations of CPA inhibitor (N-acyl-N-hydroxy-β-phenylalanines), and the substrate. The mixture was incubated at 37°C for a specified period to allow the enzymatic reaction. The release of hippuric acid, a product of substrate hydrolysis, was measured spectrophotometrically at a specific wavelength. The initial reaction rates were calculated from the absorbance data, and Ki values were determined by Lineweaver-Burk linear regression analysis of the rate data obtained at multiple substrate and inhibitor concentrations [1]
|
| References | |
| Additional Infomation |
CPA inhibitor (N-acyl-N-hydroxy-β-phenylalanine) is the first reported hydroxamic acid-based carboxypeptidase A inhibitor. Its inhibitory activity is attributed to the hydroxamic acid moiety (-CONHOH) in the compound, which is thought to chelate zinc ions at the active site of the metalloenzyme CPA. Structure-activity relationship (SAR) analysis showed that the length and substitution pattern of the N-acyl chain affected the inhibitory efficacy, with shorter acyl chains (e.g., the acetyl group in compound 3a) exhibiting higher activity than longer or substituted acyl chains [1].
|
| Molecular Formula |
C18H19NO4
|
|---|---|
| Molecular Weight |
313.34776
|
| Exact Mass |
313.131
|
| CAS # |
223532-02-3
|
| PubChem CID |
44374998
|
| Appearance |
White to off-white solid powder
|
| Density |
1.274
|
| LogP |
2.39
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PONANXDRJJIGPG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H19NO4/c20-17(12-15-9-5-2-6-10-15)19(23)13-16(18(21)22)11-14-7-3-1-4-8-14/h1-10,16,23H,11-13H2,(H,21,22)
|
| Chemical Name |
2-benzyl-3-[hydroxy-(2-phenylacetyl)amino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~319.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1913 mL | 15.9566 mL | 31.9132 mL | |
| 5 mM | 0.6383 mL | 3.1913 mL | 6.3826 mL | |
| 10 mM | 0.3191 mL | 1.5957 mL | 3.1913 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
